MERCK KGAA

Merck KGaA shares dip 2.8% as market cap hits €18.4B – see latest price, 52‑week highs, and key competitors’ 24‑hour performance.

Merck KGaA shares dip 2.83% yet remain above 200‑day SMA, with Q4 earnings beating estimates. Despite a short‑term pullback, the pharma giant’s solid cash flow and innovation pipeline keep it positioned for long‑term growth.

Merck’s 1.42 % gain shows resilience: a €62.8 bn cap, solid liquidity and a bullish trend above the 200‑day SMA—ideal for investors seeking pharma‑chemical stability.